W.B. Saunders for the American Gastroenterological Association
Clinical Gastroenterology and Hepatology vol:13 issue:6 pages:1103-10
There are limited data on the effects of discontinuing infliximab therapy for Crohn's disease (CD). We investigated the long-term outcome of patients with CD who discontinued infliximab while in clinical remission, and searched for prognostic markers of continued remission after infliximab cessation.